{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:17:52Z","timestamp":1793402272779,"version":"4.5.0"},"reference-count":102,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"\n Importance<\/jats:title>\n Essential thrombocythemia, a clonal myeloproliferative neoplasm with excessive platelet production, is associated with an increased risk of thrombosis and bleeding. The annual incidence rate of essential thrombocythemia in the US is 1.5\/100\u202f000 persons.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n Patients with essential thrombocythemia have a persistent platelet count of 450\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/L or greater. The differential diagnosis includes myeloproliferative neoplasms (polycythemia vera, primary myelofibrosis, chronic myeloid leukemia); inflammatory conditions such as rheumatoid arthritis and systemic lupus erythematosus; infections; splenectomy; iron deficiency anemia; and solid tumors such as lung cancer. Approximately 90% of individuals with essential thrombocythemia have genetic variants that upregulate the JAK-STAT (signal transducer and activator of transcription 5) signaling pathway, including Janus kinase 2\n (JAK2,<\/jats:italic>\n 64%), calreticulin\n (CALR<\/jats:italic>\n , 23%), and myeloproliferative leukemia virus oncogene\n (MPL<\/jats:italic>\n , 4%). The median age at diagnosis of essential thrombocythemia is 59 years. The median overall survival exceeds 35 years in those diagnosed at 40 years or younger. Patients with essential thrombocythemia are at increased risk of arterial thrombosis (11%), venous thrombosis (7%), and hemorrhagic complications (8%). Thrombosis risk is increased among those with a history of thrombosis, age older than 60 years, a\n JAK2<\/jats:italic>\n gene variant, and cardiovascular risk factors (eg, hypertension, diabetes mellitus, hyperlipidemias, tobacco use). Use of aspirin (81-100 mg\/d) is suggested for most patients with essential thrombocythemia to lower thrombosis risk. In a retrospective study of 300 affected patients with a low thrombosis risk (younger than 60 years with no prior thrombosis), those not taking aspirin (100 mg\/d) had a risk of arterial thrombosis of 9.4\/1000 patient-years and a venous thrombosis risk of 8.2\/1000 patient years; cardiovascular risk factors were associated with a higher risk of arterial thrombi (incidence rate ratio, 2.5 [95% CI, 1.02-6.1]), and a\n JAK2<\/jats:italic>\n gene variant was associated with increased risk of venous thrombosis (incidence rate ratio, 4.0 [95% CI, 1.2-12.9]). In a randomized trial of 114 patients at higher risk for thrombosis (age older than 60 years or a prior thrombotic event), cytoreduction with hydroxyurea significantly lowered the risk of arterial or venous thrombotic events compared with no cytoreductive therapy (3.6% vs 24%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.01). At a median of 8.5 years from diagnosis, approximately 10% of patients with essential thrombocythemia develop myelofibrosis and about 3% develop acute myeloid leukemia.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Essential thrombocythemia is a rare clonal myeloproliferative neoplasm associated with an increased risk of venous and arterial thrombosis, hemorrhage, myelofibrosis, and acute myeloid leukemia. Based on individual risk factors for thrombosis, persons with essential thrombocythemia may be treated with low-dose aspirin, either alone or in combination with a cytoreductive drug such as hydroxyurea.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2024.25349","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T11:33:17Z","timestamp":1737977597000},"page":"701","source":"Crossref","is-referenced-by-count":52,"title":["Essential Thrombocythemia"],"prefix":"10.1001","volume":"333","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Gaetano","family":"Loscocco","sequence":"additional","affiliation":[{"name":"CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Szuber","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center, El Paso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"jrv240032r1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data.","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"4","key":"jrv240032r3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms\u2014trends by subgroup and age in a population-based study in Sweden.","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J Intern Med"},{"issue":"12","key":"jrv240032r4","doi-asserted-by":"publisher","first-page":"E464","DOI":"10.1002\/ajh.26377","article-title":"A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: comparison with data from a Mayo Clinic single institutional series.","volume":"96","author":"Smith","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"jrv240032r5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"jrv240032r6","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.2169\/internalmedicine.9282-21","article-title":"Causes of thrombocytosis: a single-center retrospective study of 1,202 patients.","volume":"61","author":"Edahiro","year":"2022","journal-title":"Intern Med"},{"issue":"6","key":"jrv240032r7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4021\/jocmr1125w","article-title":"Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes.","volume":"4","author":"Rose","year":"2012","journal-title":"J Clin Med Res"},{"issue":"8","key":"jrv240032r8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.mayocp.2019.01.041","article-title":"Etiologies of extreme thrombocytosis: a contemporary series.","volume":"94","author":"Hsieh","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"19","key":"jrv240032r9","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-a vs hydroxyurea in polycythemia vera and essential thrombocythemia.","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"1","key":"jrv240032r10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv240032r11","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial.","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"34","key":"jrv240032r12","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features.","volume":"36","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"jrv240032r13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"8","key":"jrv240032r14","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ajh.27418","article-title":"Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: the ARES trial.","volume":"99","author":"Rocca","year":"2024","journal-title":"Am J Hematol"},{"issue":"17","key":"jrv240032r15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"15","key":"jrv240032r16","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.","volume":"130","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"issue":"18","key":"jrv240032r17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"4","key":"jrv240032r18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41375-023-01837-9","article-title":"Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-a: a multi-center study of the German Study Group\u2013Myeloproliferative Neoplasms (GSG-MPN).","volume":"37","author":"Stegelmann","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"jrv240032r19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"20","key":"jrv240032r20","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide: a new drug for treating thrombocytosis.","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240032r21","first-page":"51","article-title":"Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.","volume":"34","author":"Petitt","year":"1997","journal-title":"Semin Hematol"},{"issue":"32","key":"jrv240032r22","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv240032r23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","article-title":"One thousand patients with essential thrombocythemia: the Mayo Clinic experience.","volume":"14","author":"Gangat","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"jrv240032r24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-023-00968-7","article-title":"One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.","volume":"14","author":"Loscocco","year":"2024","journal-title":"Blood Cancer J"},{"issue":"16","key":"jrv240032r25","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"4","key":"jrv240032r26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"jrv240032r27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajh.25294","article-title":"Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am J Hematol"},{"issue":"4, pt 2","key":"jrv240032r28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"jrv240032r29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"issue":"3","key":"jrv240032r30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.6004\/jnccn.2018.7095","article-title":"Impact of hydroxyurea on survival and risk of thrombosis among older patients with essential thrombocythemia.","volume":"17","author":"Podoltsev","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"jrv240032r31","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia.","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"issue":"2","key":"jrv240032r32","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","article-title":"Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.","volume":"111","author":"Ruggeri","year":"2008","journal-title":"Blood"},{"issue":"9","key":"jrv240032r33","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"issue":"3","key":"jrv240032r34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/ejh.13454","article-title":"Anagrelide in essential thrombocythemia (ET): results from 150 patients over 25 years by the \u201cPh1-negative Myeloproliferative Neoplasms Latium Group\u201d.","volume":"105","author":"Mazzucconi","year":"2020","journal-title":"Eur J Haematol"},{"issue":"1","key":"jrv240032r35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"jrv240032r36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":"Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.","volume":"29","author":"Fruchtman","year":"2005","journal-title":"Leuk Res"},{"issue":"6","key":"jrv240032r37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41408-018-0091-6","article-title":"Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.","volume":"8","author":"Renso","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"jrv240032r38","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.","volume":"93","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"issue":"5","key":"jrv240032r39","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.34","article-title":"Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.","volume":"6","author":"Begna","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"jrv240032r40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/10428194.2016.1187269","article-title":"Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.","volume":"58","author":"Douglas","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"jrv240032r41","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"issue":"24","key":"jrv240032r42","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations.","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"4","key":"jrv240032r43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia.","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"issue":"13","key":"jrv240032r44","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/bloodadvances.2022007023","article-title":"1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events.","volume":"6","author":"Gangat","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"jrv240032r45","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1002\/ajh.26423","article-title":"Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia.","volume":"97","author":"Farrukh","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"jrv240032r46","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1111\/jth.15834","article-title":"Site-specific venous thrombosis in essential thrombocythemia: impact on subsequent vascular events and survival.","volume":"20","author":"Gangat","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"jrv240032r47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-021-00417-3","article-title":"Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.","volume":"11","author":"Barbui","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"jrv240032r48","doi-asserted-by":"publisher","first-page":"E182","DOI":"10.1002\/ajh.26137","article-title":"Extreme thrombocytosis in low-risk essential thrombocythemia: retrospective review of vascular events and treatment strategies.","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"issue":"23","key":"jrv240032r49","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"jrv240032r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106459","article-title":"Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.","volume":"98","author":"How","year":"2020","journal-title":"Leuk Res"},{"issue":"11","key":"jrv240032r51","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.3324\/haematol.2015.131458","article-title":"Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.","volume":"100","author":"Rumi","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"jrv240032r52","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ajh.21504","article-title":"Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry.","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"jrv240032r53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation.","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"issue":"10","key":"jrv240032r54","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/ajh.27416","article-title":"Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia\u2014a Mayo Clinic study of 200 pregnancies.","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"jrv240032r55","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1002\/cncr.21891","article-title":"Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.","volume":"106","author":"Gangat","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"jrv240032r56","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups.","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"jrv240032r57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bvth.2024.100026","article-title":"Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures.","volume":"1","author":"Szuber","year":"2024","journal-title":"Blood Vessels Thromb Haemost"},{"issue":"2","key":"jrv240032r58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases.","volume":"95","author":"Sant\u2019Antonio","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"jrv240032r59","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/ajh.26336","article-title":"Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases.","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"jrv240032r60","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"8","key":"jrv240032r61","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"jrv240032r62","doi-asserted-by":"publisher","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients.","volume":"125","author":"Mital","year":"2015","journal-title":"Pol Arch Med Wewn"},{"issue":"4","key":"jrv240032r63","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11239-015-1218-2","article-title":"Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.","volume":"40","author":"Samuelson","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"jrv240032r64","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"jrv240032r65","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera\u2014a systematic review and meta-analysis.","volume":"35","author":"Bewersdorf","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"jrv240032r66","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review.","volume":"167","author":"Chu","year":"2017","journal-title":"Ann Intern Med"},{"issue":"25","key":"jrv240032r67","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1161\/CIRCULATIONAHA.121.053782","article-title":"Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials.","volume":"143","author":"Trifan","year":"2021","journal-title":"Circulation"},{"issue":"25","key":"jrv240032r68","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"jrv240032r69","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"jrv240032r70","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization\u2013defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"11","key":"jrv240032r71","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"26","key":"jrv240032r72","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"4","key":"jrv240032r73","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"jrv240032r74","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000936","article-title":"Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish Registry of Essential Thrombocythemia.","volume":"7","author":"Alvarez-Larr\u00e1n","year":"2023","journal-title":"Hemasphere"},{"issue":"12","key":"jrv240032r75","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/ajh.27079","article-title":"A globally applicable \u201ctriple A\u201d risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count.","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"24","key":"jrv240032r76","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv240032r77","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1093\/humrep\/dez211","article-title":"Trends in the incidence, rate and treatment of miscarriage\u2014nationwide register study in Finland, 1998-2016.","volume":"34","author":"Linnakaari","year":"2019","journal-title":"Hum Reprod"},{"issue":"9","key":"jrv240032r78","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative Neoplasms, Version 3.2022: NCCN Clinical Practice Guidelines in Oncology.","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"jrv240032r79","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome\u2013negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"19","key":"jrv240032r80","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"jrv240032r81","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-019-0225-5","article-title":"Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm\u2013associated thrombosis: a consensus-based position paper.","volume":"9","author":"Barbui","year":"2019","journal-title":"Blood Cancer J"},{"issue":"25","key":"jrv240032r82","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome.","volume":"117","author":"Tiede","year":"2011","journal-title":"Blood"},{"issue":"4","key":"jrv240032r83","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"jrv240032r84","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/s-2007-996109","article-title":"Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera.","volume":"23","author":"van Genderen","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"jrv240032r85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1365-2141.1997.3503164.x","article-title":"The effects of anagrelide on human megakaryocytopoiesis.","volume":"99","author":"Solberg","year":"1997","journal-title":"Br J Haematol"},{"issue":"8","key":"jrv240032r86","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.V79.8.1931.1931","article-title":"Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.","volume":"79","author":"Mazur","year":"1992","journal-title":"Blood"},{"issue":"12","key":"jrv240032r87","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0301-472X(01)00742-1","article-title":"Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.","volume":"29","author":"Lane","year":"2001","journal-title":"Exp Hematol"},{"issue":"10","key":"jrv240032r88","first-page":"1130","article-title":"Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis: an immunohistochemical and morphometric study of sequential trephine biopsies.","volume":"88","author":"Thiele","year":"2003","journal-title":"Haematologica"},{"issue":"6","key":"jrv240032r89","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/sj.leu.2404180","article-title":"Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage.","volume":"20","author":"Hong","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"jrv240032r90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.exphem.2005.09.009","article-title":"A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions.","volume":"34","author":"McCarty","year":"2006","journal-title":"Exp Hematol"},{"issue":"6","key":"jrv240032r91","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/jth.12959","article-title":"The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis.","volume":"13","author":"Ahluwalia","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"jrv240032r92","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1111\/j.1538-7836.2010.03970.x","article-title":"Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction.","volume":"8","author":"Ahluwalia","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"jrv240032r93","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000268","article-title":"Anagrelide modulates proplatelet formation resulting in decreased number and increased size of platelets.","volume":"3","author":"Miyashita","year":"2019","journal-title":"Hemasphere"},{"issue":"5","key":"jrv240032r94","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.3324\/haematol.2018.214841","article-title":"Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells.","volume":"105","author":"Takaishi","year":"2020","journal-title":"Haematologica"},{"issue":"7037","key":"jrv240032r95","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"25","key":"jrv240032r96","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv240032r97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"jrv240032r98","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/ajh.27062","article-title":"Molecular pathogenesis of myeloproliferative neoplasms: where do we stand in 2023?","volume":"98","author":"Havelange","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"jrv240032r99","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"3","key":"jrv240032r100","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"5-6","key":"jrv240032r101","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s002770050345","article-title":"Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma.","volume":"75","author":"van Genderen","year":"1997","journal-title":"Ann Hematol"},{"issue":"7","key":"jrv240032r102","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.","volume":"13","author":"Lancellotti","year":"2015","journal-title":"J Thromb Haemost"},{"key":"jrv240032r2","first-page":"1703","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms.","volume-title":"Leukemia","author":"Khoury","year":"2022"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2829595\/jama_tefferi_2025_rv_240032_1739817659.09913.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:08:11Z","timestamp":1740481691000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2829595"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.25349","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}